#USA #Boston #medical technology #Haemonetics #Martin Madaus

Martin Madaus Joins Haemonetics Board of Directors

Haemonetics Corporation, a leading global medical technology company, has officially appointed Martin Madaus to its Board of Directors as of July 24, 2026. The election takes place at a strategic time as the company continues its pursuit of innovation within the healthcare sector, aiming to enhance patient outcomes through advanced medical solutions.

Extensive Experience in Healthcare Management

Dr. Madaus has amassed over three decades of leadership in the diagnostics and life sciences fields. His wealth of experience covers a range of significant roles, from being a chief executive officer to serving on various boards. Currently, he holds the position of Senior Operating Executive at The Carlyle Group, where he has been instrumental in advising healthcare investments and monitoring portfolio performance since 2019.

Before this, he was at the helm of Ortho Clinical Diagnostics, guiding the company through a crucial business turnaround after it separated from Johnson & Johnson, and was pivotal in establishing it as a top global provider of in vitro diagnostic solutions. Dr. Madaus’s former role as Chairman, President, and CEO of Millipore Corporation was equally transformative, where he drove the organization’s evolution into a premier life sciences entity, ultimately leading to its acquisition by Merck KGaA in 2010. Moreover, he also has a history with Roche Diagnostics North America, where he served as President and CEO, enhancing operational performance across the board.

Active Leadership Beyond Haemonetics

In addition to his executive roles, Dr. Madaus actively participates as a board leader in several organizations. He chairs the Board of Repligen Corporation and holds a position on the board of directors at Azenta, Inc. His broad experience across healthcare companies showcases his adeptness at operational and commercial leadership, which is crucial as Haemonetics seeks to expand its influence in promising market segments while enhancing its long-term value for patients, clients, and shareholders.

Ellen Zane, the Chair of Haemonetics' Board of Directors, expressed enthusiasm about the addition of Dr. Madaus: "Martin has built and transformed some of the world's most prominent healthcare firms, and that experience will significantly benefit our Board. His history of successfully managing complex global organizations while driving operational excellence aligns perfectly with our mission to continue serving our customers and stakeholders effectively."

About Haemonetics

Haemonetics Corporation specializes in advancing healthcare through innovative technology. Its offerings include cutting-edge apheresis solutions that improve donor satisfaction and operational efficiency for plasma and blood collection. Furthermore, the company provides Blood Management Technologies intended to optimize the treatment decision-making process regarding blood product management. Their Interventional Technologies, which feature advanced vascular closure systems and sensor-guided technologies, are designed to enhance procedural outcomes and improve overall patient experiences. For additional information about the company's initiatives and technologies, you can visit Haemonetics' official website.

Haemonetics remains committed to evolving healthcare practices, and the inclusion of Martin Madaus on its Board is a significant step forward in enhancing its leadership competency and advancing patient care globally.